Cytek Biosciences Inc

CTKB

Company Profile

  • Business description

    Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.

  • Contact

    47215 Lakeview Boulevard
    FremontCA94538
    USA

    T: +1 877 922-9835

    https://www.cytekbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Devices

    Fiscal Year End

    31 December 2026

    Employees

    702

Stocks News & Analysis

stocks

SpaceX rally continues, expanding sky-high valuations

SpaceX has risen 50% from its IPO price to become the second-most-expensive stock under Morningstar’s coverage.
stocks

This US AI champion’s stock is too cheap to ignore

Even as competition looks likely to build, the company remains a leading wide-moat business securely at the center of the AI ecosystem.
stocks

Why SpaceX is coming to your Super Fund

Most Australians will end up owning SpaceX — whether they like it or not.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,047.3025.90-0.29%
CAC 408,421.1446.84-0.55%
DAX 4024,985.8240.98-0.16%
Dow JONES (US)51,564.7072.150.14%
FTSE 10010,363.2736.43-0.35%
HKSE23,924.81387.35-1.59%
NASDAQ26,517.93496.281.91%
Nikkei 22571,250.06196.570.28%
NZX 50 Index13,495.63132.320.99%
S&P 5007,500.5880.481.08%
S&P/ASX 2008,828.7027.90-0.32%
SSE Composite Index4,090.4817.59-0.43%

Market Movers